GADD45B and cancer: These clinical trials showed that the cancer-selective pharmacodynamic response of DTP3, the co-inhibitor of the JNK-activating kinase MKK7, and the NFκB-regulated antiapoptotic factor GADD45β could be of clinical value through GADD45B expression in multiple myeloma, which was confirmed to be effective in a subsequent clinical trial (146).